\
&
Contact us
\
&
Contact us
Published on | 19 hours ago
Programmes Enhancing EU R&I Horizon EuropeThe Commission launched the "Call for Evidence" to improve the general environment for generating innovation, reducing fragmentation and boosting the EU’s competitiveness. This initiative aims to strengthen R&D investment and bring it up to the 3% GDP target. It will focus research support more on strategic priorities, strengthen alignment between the EU and Member States’ funding priorities, and promote the free movement of knowledge and talent across Europe.
The Call for Evidence (describing the problem, the need of this action, the policy options, ..) is the first step of the consultation process. The next step entails a public stakeholder consultation on questions regarding the ERA Act specific intervention areas, that will follow this call for evidence.
For more details and how to give feedback: website link
Deadline for input: 10 September 2025
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
